ACCIPIO® AI-powered tools assess non-contrast head CT images for intracranial hemorrhage prioritization and provide slice-level annotation
ACCIPIO® AI-powered tools assess non-contrast head CT images for intracranial hemorrhage prioritization and provide slice-level annotation
Edinburgh, UK & Tel Aviv, Israel – December 4, 2019
Blackford, the centralized medical imaging platform, today announced that MaxQ AI’s FDA-cleared and CE Marked ACCIPIO® ICH applications for stroke, traumatic brain injury, and head trauma are now available on the Blackford Platform.
Developed by MaxQ AI, the Accipio solutions use artificial intelligence in the assessment of non-contrast head CT images for suspected intracranial hemorrhage (ICH). Accipio IxTM is intended for identification and prioritization, while Accpio AxTM also includes slice-level annotation.
“We’re excited to partner with MaxQ AI and offer the Accipio applications to our customers,” said Ben Panter, CEO, Blackford Analysis. “Since every minute matters for TBI, trauma, and stroke patients, the Accipio algorithms promise to help ensure the right care is delivered faster – improving quality, helping avoid poor patient outcomes, while decreasing costs.”
MaxQ AI’s FDA-cleared and CE Marked ACCIPIO® ICH applications for stroke, traumatic brain injury, and head trauma on display on the Blackford Platform during the RSNA 2019 Annual Meeting this week in Chicago
The cost of a missed ICH can be significant, but the economic cost of treating a misdiagnosed patient is nothing compared to the devastation to families and loved ones. Even being able to divert only one patient per year to wellness from stroke care represents a significant saving for a hospital and makes a lifetime of difference to patients and their families.
Fully integrated with existing systems, Blackford Platform simplifies the implementation and management of multiple imaging applications and AI algorithms, and reduces load on PACS. New applications can easily be added to the image-processing platform, reducing implementation time, costs, and long-term maintenance.
“Our partnership with Blackford will expand access to our innovative AI-powered ICH solutions for stroke, TBI, and head trauma to radiologists and care providers worldwide, who trust Blackford as a valued partner to deliver quality solutions,” said Gene Saragnese, CEO at MaxQ AI. “We view this as a powerful collaboration that will bridge the technology divide to enable more and more hospitals and healthcare organizations to seamlessly integrate our ACCIPIO® platform.”
About MaxQ AI, Ltd.
MaxQ AI is at the forefront of Medical Diagnostic AI. We are transforming healthcare by empowering physicians to provide “smarter care” with artificial intelligence (AI) clinical insights. Based in Tel Aviv, Israel and Andover, MA, USA, our team of deep learning and machine vision experts develop innovative software that uses AI to interpret medical images and surrounding patient data. Working with world-class clinical and industry partners, our software enables physicians to make faster, more accurate decisions when diagnosing stroke, traumatic brain injury and other serious conditions. To learn more, visit www.maxq.ai or follow us on Twitter and LinkedIn.
About Blackford
Blackford provides a single platform to quickly access and manage a curated marketplace of regulatory approved medical image analysis applications and AI algorithms that add clinical value. Easily integrated into existing workflows, the platform provides actionable information that allows healthcare providers to use imaging information smartly and reduce the cost of care, while improving diagnostic confidence and patient outcomes. Founded in 2010, and with operations in the United Kingdom and the United States, Blackford Analysis is backed by TRI Cap, Old College Capital, and Archangel Investors, one of the UK’s leading business angel syndicates. www.blackfordanalysis.com
###
Media Contact
For MaxQ AI:
Travis Small
P: +1 617-538-9041
For Blackford:
Greg Kingston
P: +44 131 6688 411
